Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Mayo Clinic
UNC Lineberger Comprehensive Cancer Center
University of Arizona
City of Hope Medical Center
Incyte Corporation
Incyte Corporation
Fate Therapeutics
Brown University
SymBio Pharmaceuticals
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
University of California, Davis
Wake Forest University Health Sciences
Aptevo Therapeutics